
Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (11): 693-697.doi: 10.3760/cma.j.cn371439-20210714-00137
• Reviews • Previous Articles Next Articles
					
													Shi Yue, Li Shen, Feng Jifeng(
)
												  
						
						
						
					
				
Received:2021-07-14
															
							
																	Revised:2021-08-15
															
							
															
							
																	Online:2021-11-08
															
							
																	Published:2021-12-14
															
						Contact:
								Feng Jifeng   
																	E-mail:jifeng_feng@163.com
																					Shi Yue, Li Shen, Feng Jifeng. Treatment options for colorectal cancer primary lesions with unresectable metastases at risk of acute abdomen[J]. Journal of International Oncology, 2021, 48(11): 693-697.
| [1] |  
											 Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3):145-164. DOI: 10.3322/caac.21601. 
																							 doi: 10.3322/caac.v70.3  | 
										
| [2] |  
											 Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI: 10.3322/caac.21338. 
																							 doi: 10.3322/caac.21338  | 
										
| [3] |  
											 Hu Z, Ding J, Ma Z, et al. Quantitative evidence for early metastatic seeding in colorectal cancer[J]. Nat Genet, 2019, 51(7):1113-1122. DOI: 10.1038/s41588-019-0423-x. 
																							 doi: 10.1038/s41588-019-0423-x  | 
										
| [4] |  
											 Hellman S, Weichselbaum R. Oligometastases[J]. J Clin Oncol, 1995, 13(1):8-10. DOI: 10.1200/JCO.1995.13.1.8. 
																							 pmid: 7799047  | 
										
| [5] |  
											 Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27(8):1386-1422. DOI: 10.1093/annonc/mdw235. 
																							 doi: 10.1093/annonc/mdw235 pmid: 27380959  | 
										
| [6] |  
											 Govaert KM, Jongen JMJ, Kranenburg O, et al. Surgery-induced tumor growth in (metastatic) colorectal cancer[J]. Surg Oncol, 2017, 26(4):535-543. DOI: 10.1016/j.suronc.2017.10.004. 
																							 doi: S0960-7404(17)30328-6 pmid: 29113675  | 
										
| [7] |  
											 Sultana A, Meng R, Piantadosi C, et al. Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South Australia[J]. HPB (Oxford), 2018, 20(4):340-346. DOI: 10.1016/j.hpb.2017.10.005. 
																							 doi: 10.1016/j.hpb.2017.10.005  | 
										
| [8] |  
											 Thompson R, Cheung P, Chu W, et al. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: dose and site of metastases matter[J]. Radiother Oncol, 2020, 142:236-245. DOI: 10.1016/j.radonc.2019.08.018. 
																							 doi: S0167-8140(19)33064-6 pmid: 31543287  | 
										
| [9] |  
											 Löffler MW, Nussbaum B, Jäger G, et al. A non-interventional clinical trial assessing immune responses after radiofrequency ablation of liver metastases from colorectal cancer[J]. Front Immunol, 2019, 10:2526. DOI: 10.3389/fimmu.2019.02526. 
																							 doi: 10.3389/fimmu.2019.02526 pmid: 31803175  | 
										
| [10] |  
											 Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS[J]. Ann Oncol, 2018, 29(1):44-70. DOI: 10.1093/annonc/mdx738. 
																							 doi: 10.1093/annonc/mdx738 pmid: 29155929  | 
										
| [11] |  
											 Ahmed S, Leis A, Chandra-Kanthan S, et al. Surgical management of the primary tumor in stage Ⅳ colorectal cancer: a confirmatory retrospective cohort study[J]. J Cancer, 2016, 7(7):837-845. DOI: 10.7150/jca.14717. 
																							 doi: 10.7150/jca.14717  | 
										
| [12] |  
											 Karoui M, Roudot-Thoraval F, Mesli F, et al. Primary colectomy in patients with stage Ⅳ colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study[J]. Dis Colon Rectum, 2011, 54(8):930-938. DOI: 10.1097/DCR.0b013e31821cced0. 
																							 doi: 10.1097/DCR.0b013e31821cced0 pmid: 21730780  | 
										
| [13] |  
											 Park EJ, Baek JH, Choi GS, et al. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous, unresectable metastasis: a multicenter randomized controlled trial[J]. Cancers (Basel), 2020, 12(8):2306. DOI: 10.3390/cancers12082306. 
																							 doi: 10.3390/cancers12082306  | 
										
| [14] |  
											 Simillis C, Kalakouti E, Afxentiou T, et al. Primary tumor resection in patients with incurable localized or metastatic colorectal cancer: a systematic review and meta-analysis[J]. World J Surg, 2019, 43(7):1829-1840. DOI: 10.1007/s00268-019-04984-2. 
																							 doi: 10.1007/s00268-019-04984-2  | 
										
| [15] |  
											 Nitsche U, Stöß C, Stecher L, et al. Meta-analysis of outcomes following resection of the primary tumour in patients presenting with metastatic colorectal cancer[J]. Br J Surg, 2018, 105(7):784-796. DOI: 10.1002/bjs.10682. 
																							 doi: 10.1002/bjs.10682 pmid: 29088493  | 
										
| [16] |  
											 Hu CY, Bailey CE, You YN, et al. Time trend analysis of primary tumor resection for stage Ⅳ colorectal cancer: less surgery, improved survival[J]. JAMA Surg, 2015, 150(3):245-251. DOI: 10.1001/jamasurg.2014.2253. 
																							 doi: 10.1001/jamasurg.2014.2253  | 
										
| [17] |  
											 Shapiro M, Rashid NU, Whang EE, et al. Trends and predictors of resection of the primary tumor for patients with stage Ⅳ colorectal cancer[J]. J Surg Oncol, 2015, 111(7):911-916. DOI: 10.1002/jso.23906. 
																							 doi: 10.1002/jso.23906 pmid: 25919984  | 
										
| [18] |  
											 Scheer MG, Sloots CE, van der Wilt GJ, et al. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases[J]. Ann Oncol, 2008, 19(11):1829-1835. DOI: 10.1093/oxfordjournals.annonc.a058345. 
																							 doi: 10.1093/annonc/mdn398 pmid: 18662955  | 
										
| [19] |  
											 Fiori E, Lamazza A, Schillaci A, et al. Palliative management for patients with subacute obstruction and stage Ⅳ unresectable rectosigmoid cancer: colostomy versus endoscopic stenting: final results of a prospective randomized trial[J]. Am J Surg, 2012, 204(3):321-326. DOI: 10.1016/j.amjsurg.2011.11.013. 
																							 doi: 10.1016/j.amjsurg.2011.11.013  | 
										
| [20] |  
											 Pothuri B, Vaidya A, Aghajanian C, et al. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series[J]. Gynecol Oncol, 2003, 89(2):306-313. DOI: 10.1016/s0090-8258(03)00073-8. 
																							 doi: 10.1016/S0090-8258(03)00073-8  | 
										
| [21] | Parveen Z, Qureshi AN, Akbar M, et al. Palliative surgery for intestinal obstruction due to recurrent ovarian cancer[J]. J Ayub Med Coll Abbottabad, 2009, 21(1):135-136. | 
| [22] |  
											 Bankole AO, Osinowo AO, Adesanya AA. Predictive factors of management outcome in adult patients with mechanical intestinal obstruction[J]. Niger Postgrad Med J, 2017, 24(4):217-223. DOI: 10.4103/npmj.npmj_143_17. 
																							 doi: 10.4103/npmj.npmj_143_17  | 
										
| [23] |  
											 Spears H, Petrelli NJ, Herrera L, et al. Treatment of bowel obstruction after operation for colorectal carcinoma[J]. Am J Surg, 1988, 155(3):383-386. DOI: 10.1016/s0002-9610(88)80095-3. 
																							 pmid: 3344898  | 
										
| [24] |  
											 Chang HK, Min BS, Ko YT, et al. Obstructive colitis proximal to obstructive colorectal carcinoma[J]. Asian J Surg, 2009, 32(1):26-32. DOI: 10.1016/S1015-9584(09)60005-1. 
																							 doi: 10.1016/S1015-9584(09)60005-1  | 
										
| [25] |  
											 Winner M, Mooney SJ, Hershman DL, et al. Management and outcomes of bowel obstruction in patients with stage Ⅳ colon cancer: a population-based cohort study[J]. Dis Colon Rectum, 2013, 56(7):834-843. DOI: 10.1097/DCR.0b013e31-8294ed6b. 
																							 doi: 10.1097/DCR.0b013e318294ed6b pmid: 23739189  | 
										
| [26] |  
											 Kolomainen DF, Daponte A, Barton DP, et al. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)[J]. Gynecol Oncol, 2012, 125(1):31-36. DOI: 10.1016/j.ygyno.2011.11.007. 
																							 doi: 10.1016/j.ygyno.2011.11.007 pmid: 22082991  | 
										
| [27] | Jackson P, Vigiola Cruz M. Intestinal obstruction: evaluation and management[J]. Am Fam Physician, 2018, 98(6):362-367. | 
| [28] |  
											 Jaffe T, Thompson WM. Large-bowel obstruction in the adult: classic radiographic and CT findings, etiology, and mimics[J]. Radiology, 2015, 275(3):651-663. DOI: 10.1148/radiol.2015140916. 
																							 doi: 10.1148/radiol.2015140916  | 
										
| [29] | Cousins SE, Tempest E, Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer[J]. Cochrane Database Syst Rev, 2016, 2016(1): CD002764. DOI: 10.1002/14651858.CD002764.pub2. | 
| [30] |  
											 Watson J, Mannix K, Matthewson K. Percutaneous endoscopic gastroenterostomy and jejunal extension for gastric stasis in pancreatic carcinoma[J]. Palliat Med, 1997, 11(5):407-410. DOI: 10.1177/026921639701100512. 
																							 pmid: 9472599  | 
										
| [31] | Wangensteen OH. Historical aspects of the management of acute intestinal obstruction[J]. Surgery, 1969, 65(2):363-383. | 
| [32] |  
											 Laval G, Marcelin-Benazech B, Guirimand F, et al. Recom-mendations for bowel obstruction with peritoneal carcinomatosis[J]. J Pain Symptom Manage, 2014, 48(1):75-91. DOI: 10.1016/j.jpainsymman.2013.08.022. 
																							 doi: 10.1016/j.jpainsymman.2013.08.022  | 
										
| [33] |  
											 Chen TM, Huang YT, Wang GC. Outcome of colon cancer initially presenting as colon perforation and obstruction[J]. World J Surg Oncol, 2017, 15(1):164. DOI: 10.1186/s12957-017-1228-y. 
																							 doi: 10.1186/s12957-017-1228-y  | 
										
| [34] |  
											 McQuade RM, Stojanovska V, Stavely R, et al. Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15[J]. Br J Pharmacol, 2018, 175(4):656-677. DOI: 10.1111/bph.14114. 
																							 doi: 10.1111/bph.v175.4  | 
										
| [35] |  
											 McQuade RM, Carbone SE, Stojanovska V, et al. Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice[J]. Br J Pharmacol, 2016, 173(24):3502-3521. DOI: 10.1111/bph.13646. 
																							 doi: 10.1111/bph.v173.24  | 
										
| [36] |  
											 Winner M, Mooney SJ, Hershman DL, et al. Incidence and predictors of bowel obstruction in elderly patients with stage Ⅳ colon cancer: a population-based cohort study[J]. JAMA Surg, 2013, 148(8):715-722. DOI: 10.1001/jamasurg.2013.1. 
																							 doi: 10.1001/jamasurg.2013.1 pmid: 23740130  | 
										
| [37] |  
											 Anwar S, Peter MB, Dent J, et al. Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review[J]. Colorectal Dis, 2012, 14(8):920-930. DOI: 10.1111/j.1463-1318.2011.02817.x. 
																							 doi: 10.1111/j.1463-1318.2011.02817.x pmid: 21899714  | 
										
| [38] |  
											 Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage Ⅳ colorectal cancer and unresectable metastases[J]. World J Surg, 2011, 35(3):684-692. DOI: 10.1007/s00268-010-0891-8. 
																							 doi: 10.1007/s00268-010-0891-8 pmid: 21181473  | 
										
| [39] |  
											 Kanemitsu Y, Shitara K, Mizusawa J, et al. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial[J]. J Clin Oncol, 2021, 39(10):1098-1107. DOI: 10.1200/JCO.20.02447. 
																							 doi: 10.1200/JCO.20.02447 pmid: 33560877  | 
										
| [40] |  
											 Søreide K. Resection of asymptomatic primary tumour in unresectable stage Ⅳ colorectal cancer: time to move on from propensity matched scores to randomized controlled trials[J]. Int J Cancer, 2016, 139(9):1927-1929. DOI: 10.1002/ijc.30244. 
																							 doi: 10.1002/ijc.30244 pmid: 27400774  | 
										
| [41] |  
											 Gelsomino F, Spallanzani A, Orsi G, et al. To resect or not to resect: the hamletic dilemma of primary tumor resection in patients with asymptomatic stage Ⅳ colorectal cancer[J]. Crit Rev Oncol Hematol, 2018, 132:154-160. DOI: 10.1016/j.critrevonc.2018.10.001. 
																							 doi: S1040-8428(18)30201-4 pmid: 30447921  | 
										
| [42] | Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis-current evidence and potential clinical applications[J]. Aliment Pharmacol Ther, 2014, 40(5):409-421. DOI: 10.1111/apt.12878. | 
| [43] |  
											 Ferreira M, Andreyev HJ. Editorial: gut microbiota and chemotherapy- or radiation-induced gastrointestinal mucositis[J]. Aliment Pharmacol Ther, 2014, 40(6):733-734. DOI: 10.1111/apt.12905. 
																							 doi: 10.1111/apt.2014.40.issue-6  | 
										
| [44] |  
											 Zeilstra J, Joosten SP, van Andel H, et al. Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling[J]. Oncogene, 2014, 33(5):665-670. DOI: 10.1038/onc.2012.611. 
																							 doi: 10.1038/onc.2012.611 pmid: 23318432  | 
										
| [45] |  
											 Gregorieff A, Liu Y, Inanlou MR, et al. Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer[J]. Nature, 2015, 526(7575):715-718. DOI: 10.1038/nature15382. 
																							 doi: 10.1038/nature15382  | 
										
| [46] |  
											 Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis[J]. Nature, 2018, 554(7693):538-543. DOI: 10.1038/nature25492. 
																							 doi: 10.1038/nature25492  | 
										
| [47] |  
											 Pietrantonio F, Aprile G, Rimassa L, et al. A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer[J]. Radiother Oncol, 2015, 117(2):315-321. DOI: 10.1016/j.radonc.2015.08.023. 
																							 doi: 10.1016/j.radonc.2015.08.023 pmid: 26347495  | 
										
| [48] |  
											 Lv X, Yu H, Gao P, et al. A nomogram for predicting bowel obstruction in preoperative colorectal cancer patients with clinical characteristics[J]. World J Surg Oncol, 2019, 17(1):21. DOI: 10.1186/s12957-019-1562-3. 
																							 doi: 10.1186/s12957-019-1562-3  | 
										
| [49] |  
											 Kijima S, Sasaki T, Nagata K, et al. Preoperative evaluation of colorectal cancer using CT colonography, MRI, and PET/CT[J]. World J Gastroenterol, 2014, 20(45):16964-16975. DOI: 10.3748/wjg.v20.i45.16964. 
																							 doi: 10.3748/wjg.v20.i45.16964  | 
										
| [50] | Pisano M, Zorcolo L, Merli C, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation[J]. World J Emerg Surg, 2018, 13:36. DOI: 10.1186/s13017-018-0192-3. | 
| [51] |  
											 Lee NK, Kim S, Hong SB, et al. CT diagnosis of non-traumatic gastrointestinal perforation: an emphasis on the causes[J]. Jpn J Radiol, 2020, 38(2):101-111. DOI: 10.1007/s11604-019-00910-7. 
																							 doi: 10.1007/s11604-019-00910-7  | 
										
| [1] | Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375. | 
| [2] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. | 
| [3] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285. | 
| [4] | Wang Zihao, Wang Yu, Yang Xin, He Yi, Mo Xingkui, Yuan Tao. Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma [J]. Journal of International Oncology, 2024, 51(4): 239-244. | 
| [5] | Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118. | 
| [6] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474. | 
| [7] | Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273. | 
| [8] | Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163. | 
| [9] | Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190. | 
| [10] | Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722. | 
| [11] | Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687. | 
| [12] | Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46. | 
| [13] | Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559. | 
| [14] | He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563. | 
| [15] | Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477. | 
| Viewed | ||||||
| 
										Full text | 
									
										 | 
								|||||
| 
										Abstract | 
									
										 | 
								|||||